Editorial and Artistic Control Sample Clauses

Editorial and Artistic Control. Medscape will have exclusive editorial and artistic control over the selection of any of its intellectual property or other proprietary materials (including Trademarks and Medscape Content) integrated or appearing in any of the Products or Services developed or to be developed under this Agreement, and the determination of the design and look and feel of all visual elements relating to such proprietary materials (including any in-context, integrated links to any Medscape Website from within any such Products). NDC will have exclusive editorial and artistic control over the selection of any of its intellectual property and other proprietary materials (including Trademarks and content) integrated or appearing in any of the Products or Services developed or to be developed under this Agreement, and except as provided in the immediately following sentence and the provisos thereto, the determination of the design and look and feel of all visual elements relating to such proprietary materials. Medscape shall have the right, in its discretion, to determine the visual elements, the placement, and the design and look and feel, of such of NDC's proprietary materials as may appear or be integrated in any Medscape Website, provided that Medscape shall have no right to request the alteration or other modification of any of NDC's Trademarks, 18 19 and provided further, that NDC shall have the right to approve any such determination (which shall not be unreasonably withheld or delayed).
Sample 1Sample 2
AutoNDA by SimpleDocs
Editorial and Artistic Control. Medscape will have exclusive editorial and artistic control over the Medscape Consumer Site and all elements thereof, including the selection of the Medscape Content and Third Party Components, and the design and look and feel of all visual elements (including the End-User Tools), appearing in the Medscape Consumer Site. Medscape acknowledges that the exercise of its rights to editorial and artistic control may materially alter the Specifications as then in effect, and that the same may result in an extension of, or other change to the relevant Delivery and Milestone Schedule and/or additional expense to Medscape. SoftWatch will promptly notify Medscape if any change requested by Medscape will result in any such extension of, or
Sample 1
Editorial and Artistic Control. Contractor waives any right to interfere with or to prevent the exercise of Producer’s sole and absolute discretion with regard to the Film, including all matters of direction, artistic taste, and judgment. It is understood and agreed that Producer shall retain content, editorial, and technical control of the Services and the Film at all times.
Sample 1

Related to Editorial and Artistic Control

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Approval and Completion If any dispute regarding the design of the Tenant Improvements is not settled within 10 business days after notice of such dispute is delivered by one party to the other, Tenant may make the final decision regarding the design of the Tenant Improvements, provided (i) Tenant acts reasonably and such final decision is either consistent with or a compromise between Landlord’s and Tenant’s positions with respect to such dispute, (ii) that all costs and expenses resulting from any such decision by Tenant shall be payable out of the TI Fund (as defined in Section 5(d) below), and (iii) Tenant’s decision will not affect the base Building, structural components of the Building or any Building systems (in which case Landlord shall make the final decision). Any changes to the TI Construction Drawings following Landlord’s and Tenant’s approval of same requested by Tenant shall be processed as provided in Section 4 hereof.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Research Reports Distributor acknowledges that Dealer may prepare research reports relating to the Fund that are not to be used for marketing purposes (“Research Reports”). Distributor hereby authorizes Dealer to use the name of the Fund, Distributor and BREDS in Research Reports.

  • Research Records Each Party shall maintain records of each Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Program. All laboratory notebooks shall be maintained for no less than the term of any Patent issuing therefrom. All other records shall be maintained by each Party during the relevant Research Term and for [**] thereafter. All such records of a Party shall be considered such Party’s Confidential Information.

  • Statistical and Market Data Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included in the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Independent Development Receiving Party may currently or in the future be developing information internally, or receiving information internally, or receiving information from other parties that may be similar to the Disclosing Party's Confidential Information. Accordingly, nothing in this Agreement will be construed as a representation or inference that Receiving Party will not develop or have developed products or services, that, without violation of this Agreement, might compete with the products or systems contemplated by the Disclosing Party's Confidential Information.

Time is Money Join Law Insider Premium to draft better contracts faster.